Publication | Closed Access

Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis

InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune DiseaseMedicinePharmacologyImmunologySerum LevelsInflammatory Rheumatic DiseasePsoriatic ArthritisNf-kappab LigandRheumatoid ArthritisDrug Discovery